Pancreatic ductal adenocarcinoma (PDAC), commonly referred to as pancreatic cancer,
ranks among the leading causes of cancer-related deaths in the Western world due to …

Gemcitabine is the first-line treatment for pancreatic adenocarcinoma, but is increasingly
used to treat breast, bladder, and non-small cell lung cancers. Despite such broad use …

Pancreatic ductal adenocarcinoma, an exocrine tumor, is the most common type of cancer of
the pancreas and one of the top five most prominent causes of cancer-associated mortality …

Clinical refractoriness to nucleoside analogs (eg, gemcitabine, capecitabine) is a major
scientific problem and is one of the main reasons underlying the extremely poor prognostic …

Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC),
ranks the fourth leading cause of cancer-related deaths in the western world. While the …

The diagnosis of pancreatic cancer confers a grim prognosis that has changed little over the
last 30 years. Due to the lack of any efficacious screening or biomarkers for pancreatic …

Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The
disappointing 5-year survival rate of below 5% stems from drug resistance to all known …

Pancreatic cancer is one of the most lethal types of cancer in the world. The incidence of
pancreatic cancer increases each year with no significant decrease in mortality. Pancreatic …

Pancreatic ductal adenocarcinoma (PDA) has become one of the leading causes of cancer-
related deaths across the world. A lack of durable responses to standard-of-care …

Abstract Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most chemoresistant
cancers, and current therapies targeting cancer-associated molecular pathways have not …